The 5 most recent market catalysts affecting $NRXS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 85
NeurAxis shares are trading higher. The company announced new medical policy coverage from a national health insurer for Percutaneous Electrical Nerve Field Stimulation, spanning multiple states and covering ~18 million members.
The headline indicates a major positive catalyst for NeurAxis (NRXS). New medical policy coverage from a national insurer for their PENFS technology, spanning multiple states and c…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
NeurAxis Announces New Medical Policy Coverage For PENFS From Unnamed National Health Insurer
The new medical policy coverage for PENFS from a national health insurer is a significant positive catalyst for NeurAxis (NRXS). Increased insurance coverage directly translates to…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 75
Neuraxis shares are trading lower after the company reported mixed Q2 financial results.
The mixed Q2 financial results for Neuraxis (NRXS) are a significant corporate catalyst, directly impacting its share price negatively. Investors are likely reacting to unmet expec…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
Neuraxis Q2 EPS $(0.19) Beats $(0.32) Estimate, Sales $1.929M Miss $2.000M Estimate
Neuraxis (NRXS) released its Q2 earnings, showing a mixed performance. The company successfully narrowed its losses, beating analyst EPS estimates by a significant margin, which is…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
NeurAxis Announces Additional Medical Policy Coverage For PENFS Representing Over 500,000 Covered Lives, Expanding IB-Stim Access In Mid-Atlantic Region
The additional medical policy coverage for NeurAxis's PENFS (IB-Stim) device is a direct positive catalyst for the company. Expanding access to over 500,000 covered lives in the Mi…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.